SCHEMBL1008937

SCHEMBL1008937

Clc1ccc(CCCCBr)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.53
ALOX15 P16050 1/20 0.53
KCNH2 Q12809 4/20 0.50
TAAR1 Q96RJ0 2/20 0.50
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7464785 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL8071211 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL7217191 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL7562067 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL5596095 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL11460578 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL7562217 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL7614753 0.98 KCNH2 (0.53) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL81407 0.93 TAAR1 (0.52) IGF1RALOX15KCNH2TAAR1HDAC3
SCHEMBL2177163 0.87 THRA (0.47) IGF1RALOX15HDAC1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1018548-B CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOEHRINGER MANNHEIM GMBH (DE) 1992-10-07 CN claimed
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2024-08-29 US disclosed
EP-4353713-A1 T-TYPE CALCIUM CHANNEL BLOCKER Kinki University (JP) 2024-04-17 EP disclosed
WO-2022260016-A1 T-TYPE CALCIUM CHANNEL BLOCKER 学校法人近畿大学 2022-12-15 WO disclosed
WO-2016100940-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 WO disclosed
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 US disclosed
CN-101948368-B Diphenylalkyl halide or diphenyl carboxylic acid and synthesis method thereof SHANGHAI INST ORGANIC CHEM 2013-09-25 CN disclosed
CN-102137837-A PAI-1 inhibitor INST MED MOLECULAR DESIGN INC 2011-07-27 CN disclosed
CN-101948368-A Diphenylalkyl halide or diphenyl carboxylic acid and synthesis method thereof SHANGHAI INST ORGANIC CHEM 2011-01-19 CN disclosed
EP-2272817-A1 PAI-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2011-01-12 EP disclosed
US-5512581-A ANTIINFLAMMATORY AGENT ABBOTT LABORATORIES (US) 1996-04-30 US disclosed
WO-1996002507-A1 IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1996-02-01 WO disclosed
EP-0637580-A1 Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1995-02-08 EP disclosed
US-4933367-A Carboxylic acid derivatives, processes for the preparation thereof, the use thereof, and pharmaceutical compositions which contain these compounds BOEHRINGER MANNHEIM GMBH (DE) 1990-06-12 US disclosed
EP-0226636-B1 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1989-02-08 EP disclosed
EP-0226636-A1 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS. BOEHRINGER MANNHEIM GMBH (DE) 1987-07-01 EP disclosed
WO-1987000521-A2 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1987-01-29 WO disclosed
EP-0016310-B1 MONOPHOSPHONATE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SYMPHAR S.A. (CH) 1982-09-22 EP disclosed
US-4268507-A Monophosphonate compounds as hypoglycemic and/or antiartherogenic agents SYMPHAR S.A. (CH) 1981-05-19 US disclosed
EP-0016310-A1 Monophosphonate compounds, process for their preparation and pharmaceutical compositions containing them SYMPHAR S.A. (CH) 1980-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1G, CACNA1I, CACNA1H IGF1R 2448/4885ALOX15 4111/4885KCNH2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.